Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,624 across all filing types
Latest filing 2023-01-03 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT-NMPA HAS APPROVED IND APPLICATION FOR DISITAMAB VEDOTIN FOR INJECTION, GIVEN INTRAVENOUSLY, IN COMBINATION WITH GEMCITABINE HYDROCHLORIDE FOR INJECTION, GIVEN INTRAVESICALLY, FO
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding the approval by the National Medical Products Administration (NMPA) of an investigational new drug (IND) application for a specific drug combination for treatment of non-muscle invasive bladder cancer (NMIBC). It contains no financial data, no financial statements, no management discussion of financial results, no voting results, no regulatory certifications, no share transactions, no capital changes, no earnings data, and no meeting materials. The document is an announcement of a regulatory approval related to the company's drug development pipeline. It is not a report, transcript, or financial filing. The document is relatively short (4880 characters) and is clearly an announcement of a regulatory event. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-03 English
DISCLOSEABLE TRANSACTION - PROVISION OF FINANCIAL SUPPORT
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a discloseable transaction involving the provision of financial support by the company to an associated entity. It references compliance with the Listing Rules, details of the transaction, parties involved, and implications under Chapter 14 of the Listing Rules. The document is structured as a formal announcement to shareholders and the market about a specific financial support agreement and its regulatory implications. It does not contain financial statements, detailed financial performance data, or management discussion and analysis. It is not a full annual or interim report, nor is it a call transcript or presentation. The document is a regulatory announcement about a transaction and related financial support, fitting the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories like capital update or earnings release.
2022-12-30 English
Remuneration Committee Terms of Reference
Governance Information Classification · 100% confidence The document is titled 'Remuneration Committee Terms of Reference' and details the organization, objectives, composition, duties, meetings, and reporting structure of the remuneration committee of Overseas Chinese Town (Asia) Holdings Limited. It focuses on the committee's role in recommending and overseeing remuneration policies for directors and senior management. There are no financial statements, earnings data, or regulatory filings present. The content is a governance document outlining internal rules and committee responsibilities related to remuneration. This matches the description of a Governance Information report (CGR), which covers company internal rules and governance practices, including remuneration committee terms of reference.
2022-12-30 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 29 DECEMBER 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results from an Extraordinary General Meeting (EGM) held on 29 December 2022. It details the voting outcomes on several resolutions but does not contain financial statements or detailed report content. The document is relatively short (4642 characters) and serves to inform shareholders and the public of the voting results rather than presenting a full report or detailed analysis. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-12-29 English
THE FIRST GRANT OF THE RESTRICTED SHARES UNDER THE 2022 A SHARE INCENTIVE SCHEME
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from RemeGen Co., Ltd. regarding the first grant of restricted shares under the 2022 A Share Incentive Scheme. It details the grant date, number of shares granted, participants, grant price, attribution arrangements, and performance assessment requirements. The content focuses on the issuance of restricted shares to employees and directors as part of an incentive scheme. This is a capital-related update about share grants and employee incentives, not a full financial report, earnings release, or management discussion. It is not a proxy solicitation or voting result announcement, nor is it a regulatory filing or legal proceeding. The document is an update on a capital change related to share incentives, which fits best under the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed information about the share grant, not just a brief announcement or reference to another report, so it is not RPA or RNS.
2022-12-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-12-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.